Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).
Document Type
Presentation
Publication Date
12-7-2022
Keywords
oregon; chiles
Clinical Institute
Cancer
Clinical Institute
Women & Children
Department
Oncology
Department
Earle A. Chiles Research Institute
Recommended Citation
Stanton, Sasha, "Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)." (2022). Articles, Abstracts, and Reports. 6880.
https://digitalcommons.providence.org/publications/6880
Comments
Presented at the SABCS Annual Meeting; 2022 December 7; San Antonio, TX.